Table 1.
Baseline characteristics of the study population.
| Characteristics | Child–Pugh A (n = 132) |
Child–Pugh B (n = 71) |
p Value |
|---|---|---|---|
| Demographics | |||
| Age, mean ± SD, y | 56.9 ± 11.2 | 56.0 ± 9.4 | 0.576 |
| Male sex, n (%) | 115 (87.1) | 56 (78.9) | 0.182 |
| Etiology, HBV/HCV/Other, n (%) | 111/4/17 (84.1/3.0 /12.9) |
57/4/10 (80.3/5.6/14.1) |
0.630 |
| ECOG performance status, n (%) | 0.004 | ||
| 0/1/2 | 64/57/11 (48.5/43.2/8.3) |
18/41/12 (25.4/57.7/16.9) |
|
| Tumor characteristics | |||
| BCLC stage, n (%) | 0.822 | ||
| Intermediate/Advanced | 6/126 (4.5/95.5) | 2/69 (2.8/97.2) | |
| Portal vein invasion, n (%) | 46 (34.8) | 42 (59.2) | 0.001 |
| Extrahepatic metastasis, n (%) | 120 (90.9) | 64 (90.1) | >0.999 |
| Involved disease sites, n (%) | |||
| Liver | 104 (78.8) | 66 (93.0) | 0.016 |
| Lung | 79 (59.8) | 48 (67.6) | 0.349 |
| Number of involved disease sites, n (%) | 0.959 | ||
| 1–2/≥3 | 80/52 (60.6/69.4) | 42/29 (59.2/40.8) | |
| α-Fetoprotein, median (IQR), ng/mL | 311 (10, 3392) | 2698 (44, 53727) | 0.001 |
| PIVKA-II, median (IQR), mAU/mL | 1439 (150, 9129) | 6846 (771, 57522) | <0.001 |
| Immunotherapy as systemic, n (%) | 0.218 | ||
| First-line | 2 (1.5) | 1 (1.4) | |
| Second-line | 89 (67.4) | 56 (78.9) | |
| Third-line or more | 41 (31.1) | 14 (19.7) | |
| Liver function | |||
| Child–Pugh score, n (%) | – | ||
| 5/6 | 67/65 (50.8/40.2) | – | |
| 7/8/9 | – | 41/15/15 (57.7/21.2/21.2) |
|
| Platelet count, n (%) ≥150,000/μL <150,000/μL |
65 (40.2) 67 (50.8) |
26 (36.6) 45 (63.4) |
0.115 |
| Ascites, present, n (%) | 6 (4.5) | 48 (67.6) | <0.001 |
| Albumin, median (IQR), g/dL | 3.6 (3.2, 3.9) | 2.9 (2.6, 3.2) | <0.001 |
| >3.5/2.8–3.5/<2.8, n (%) | 81/51/0 (61.4/38.6 /0.0) |
8/33/30 (11.3/46.5/42.3) |
|
| Total bilirubin, median (IQR), mg/dL | 0.7 (0.5, 0.9) | 1.3 (0.9, 2.0) | <0.001 |
| <2/2–3 />3, n (%) | 130/2/0 (98.5/1.5/0.0) |
52/12/7 (73.2/16.9/9.9) |
|
| ALBI grade, mean ± SD | −2.33 ± 0.37 | −1.54 ± 0.37 | <0.001 |
| 1/2/3, n (%) | 35/97/0 (26.5/73.5/0.0) |
0/49/22 (0.0/69.0/31.0) |
|
Abbreviations: ALBI, albumin-bilirubin; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCV, hepatitis C virus; IQR, interquartile range; PIVKA, protein induced by vitamin K absence or antagonist-II; SD, standard deviation.